Shanghai East Hospital is a general hospital in Pudong, Shanghai, China. It is a teaching hospital affiliated to Tongji University.

There are 2,000 beds in Shanghai Tongji Hospital.

During the past decade, Shanghai Tongji Hospital conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 9 clinical trials were completed, i.e. on average, 16.4% percent of trials that started reached the finish line to date. In the past 5 years, 32 clinical trials started and 9 clinical trials were completed. i.e. 28.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Shanghai Tongji Hospital" #1 sponsor was "Boehringer Ingelheim" with 6 trials, followed by "Fudan University" with 4 trials sponsored, "RenJi Hospital" with 4 trials sponsored, "Takeda" with 4 trials sponsored and "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 4 trials sponsored. Other sponsors include 44 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Shanghai Tongji Hospital" #1 collaborator was "Shanghai Tongji Hospital, Tongji University School of Medicine" with 9 trials as a collaborator, "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine" with 4 trials as a collaborator, "Changhai Hospital" with 3 trials as a collaborator, "Huashan Hospital" with 3 trials as a collaborator and "Shanghai Pudong New Area People's Hospital" with 3 trials as a collaborator. Other collaborators include 57 different institutions and companies that were collaborators in the rest 57 trials.

According to Clinical.Site data, the most researched conditions in "Shanghai Tongji Hospital" are "Asthma" (3 trials), "Esophagus Cancer" (3 trials), "Gastric Cancer" (3 trials), "Stroke" (3 trials) and "Airway Responsiveness" (2 trials). Many other conditions were trialed in "Shanghai Tongji Hospital" in a lesser frequency.

Most popular intervention types in "Shanghai Tongji Hospital" are "Drug" (50 trials), "Biological" (6 trials), "Device" (5 trials), "Other" (5 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Lansoprazole" (5 trials), "Lansoprazole Placebo" (5 trials), "Bismuth-Containing Quadruple Therapy" (2 trials) and "TAK-438" (2 trials). Other intervention names were less common.

The vast majority of trials in "Shanghai Tongji Hospital" are 66 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Shanghai Tongji Hospital". 1 are not yet recruiting, 12 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Shanghai Tongji Hospital, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Shanghai Tongji Hospital, 3 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 13 trials that are defined as “Not Applicable".